Perceptive Advisors LLC Janux Therapeutics, Inc. Transaction History
Perceptive Advisors LLC
- $2.28 Billion
- Q2 2025
A detailed history of Perceptive Advisors LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 292,686 shares of JANX stock, worth $7.1 Million. This represents 0.3% of its overall portfolio holdings.
Number of Shares
292,686
Previous 970,412
69.84%
Holding current value
$7.1 Million
Previous $26.2 Million
74.2%
% of portfolio
0.3%
Previous 1.1%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
186Shares Held
55.9MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$272 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$108 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$70.9 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$61.3 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$56.9 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.01B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...